+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Minimal Residual Disease Testing: Global Markets and Technologies

  • PDF Icon

    Report

  • 152 Pages
  • July 2023
  • Region: Global
  • BCC Research
  • ID: 5852470
Description Jump to:

The report’s scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies’ mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

Report Includes

  • 44 data tables and 45 additional tables
  • An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing
  • Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028
  • Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region
  • In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market
  • Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations
  • Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse
  • Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry
  • A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities
  • Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration
  • Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics Inc., Exact Sciences Corp., and Quest Diagnostics

Table of Contents

Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing this Study
  • Scope of Report
  • Research Methodology
  • Information Sources
  • Geographic Breakdown
Chapter 2 Summary and Highlights
  • Market Outlook
Chapter 3 Market Overview
  • Definition of Minimal Residual Disease
  • Importance of Detecting Minimal Residual Disease
  • Indications for Minimal Residual Disease Testing
  • Techniques Used for Detecting Minimal Residual Disease
Chapter 4 Market Dynamics
  • Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
  • Impact of Covid-19 on Minimal Residual Disease Testing Market
  • Regulatory Landscape
  • Clinical Laboratory Improvement Amendments of 1988 (Clia)
  • State Licensing Laws
  • The U.S. Food and Drug Administration
Chapter 5 Global Minimal Residual Disease Testing Market by Technology
  • Overview
  • Flow Cytometry
  • Polymerase Chain Reaction (Pcr)
  • Next-Generation Sequencing (Ngs)
  • Others
Chapter 6 Global Minimal Residual Disease Testing Market by Application
  • Overview
  • Hematological Malignancies
  • Leukemia
  • Lymphoma
  • Myeloma
  • Solid Tumors
  • Others
Chapter 7 Global Minimal Residual Disease Testing Market by Region
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
Chapter 8 Esg Developments
  • Importance of Esg in Minimal Residual Disease Testing Industry
  • Esg Ratings and Metrics: Understanding the Data
  • Esg Practices in the Minimal Residual Disease Testing Industry
  • Environmental Performance
  • Social Performance
  • Governance Performance
  • Future Trends
  • Research Viewpoint
Chapter 9 Emerging Technologies and Developments
  • Emerging Technologies
  • Digital Polymerase Chain Reaction (Dpcr)
Chapter 10 M&A Analysis
  • M&A Analysis
Chapter 11 Competitive Intelligence
  • Top Market Players Ranking, 2022
  • Key Strategies Adopted by Companies
  • Collaborations
  • Marketing Activity
  • New Product Launch
  • Expansion
  • Acquisition
  • Partnerships, Agreements and Alliances
  • Clinical Data Studies
  • Others
Chapter 12 Company Profiles
  • Adaptive Biotechnologies Corp.
  • Amgen Inc.
  • Astrazeneca plc
  • Bio-Rad Laboratories Inc.
  • Cergentis B.V.
  • Exact Sciences Corp.
  • Guardant Health Inc.
  • Illumina Inc. (Grail LLC)
  • Invitae
  • Invivoscribe Inc.
  • Natera Inc.
  • Neogenomics Inc.
  • Qiagen
  • Sysmex Corp.
List of Tables
Summary Table: Global Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 1: Techniques to Quantify MRD in Multiple Myeloma
Table 2: Advantages and Disadvantages of Available Techniques to Monitor MRD
Table 3: Various Liquid Biopsies for Minimal Residual Disease Testing
Table 4: Total Number of New Cancer Cases and Deaths Due to Various Cancers Globally, 2020
Table 5: Global Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 6: Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, Through 2028
Table 7: Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, Through 2028
Table 8: Global Market for Next-Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, Through 2028
Table 9: Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, Through 2028
Table 10: Global Market for Minimal Residual Disease Testing, by Application, Through 2028
Table 11: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, Through 2028
Table 12: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
Table 13: Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, Through 2028
Table 14: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, Through 2028
Table 15: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, Through 2028
Table 16: Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, Through 2028
Table 17: Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, Through 2028
Table 18: Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, Through 2028
Table 19: Global Market for Minimal Residual Disease Testing for Solid Tumors, by Region, Through 2028
Table 20: Global Market for Minimal Residual Disease Testing for Other Applications, by Region, Through 2028
Table 21: Global Market for Minimal Residual Disease Testing, by Region, Through 2028
Table 22: North American Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 23: North American Market for Minimal Residual Disease Testing, by Application, Through 2028
Table 24: North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
Table 25: Estimated Cancer Incidence and Mortality, Age Standardized Rate, by Cancer Type, EU Countries, 2020
Table 26: European Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 27: European Market for Minimal Residual Disease Testing, by Application, Through 2028
Table 28: European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
Table 29: Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 30: Asia-Pacific Market for Minimal Residual Disease Testing, by Application, Through 2028
Table 31: Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
Table 32: Rest of the World Market for Minimal Residual Disease Testing, by Technology, Through 2028
Table 33: Rest of the World Market for Minimal Residual Disease Testing, by Application, Through 2028
Table 34: Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028
Table 35: ESG Ratings and Metrics
Table 36: Environmental Performance in the Minimal Residual Disease Testing Industry
Table 37: Social Performance in the Minimal Residual Disease Testing Industry
Table 38: Governance Performance in the Minimal Residual Disease Testing Industry
Table 39: Acquisitions in the Minimal Residual Disease Testing Industry, Oct. 2020-Apr. 2023
Table 40: Collaborations: Minimal Residual Disease Testing Market, 2020-2023
Table 41: Marketing Activity: Minimal Residual Disease Testing Market, 2020-2023
Table 42: New Product Launch: Minimal Residual Disease Testing Market, 2020-2023
Table 43: Expansion: Minimal Residual Disease Testing Market, 2020-2023
Table 44: Acquisitions: Minimal Residual Disease Testing Market, 2020-2023
Table 45: Partnerships, Agreements and Alliances: Minimal Residual Disease Testing Market, 2020-2023
Table 46: Clinical Data Studies: Minimal Residual Disease Testing Market, 2020-2023
Table 47: Other Competitive Strategies: Minimal Residual Disease Testing Market, 2020-2023
Table 48: Adaptive Biotechnologies Corp.: Annual Revenue, 2022
Table 49: Adaptive Biotechnologies Corp.: Recent Developments, Nov. 2020-Apr. 2023
Table 50: Adaptive Biotechnologies Corp.: Pipeline Products
Table 51: Adaptive Biotechnologies Corp.: Product Portfolio
Table 52: Amgen Inc.: Annual Revenue, 2022
Table 53: Amgen Inc.: Recent Developments, 2019-2023
Table 54: Amgen Inc.: Product Portfolio
Table 55: AstraZeneca Plc: Annual Revenue, 2022
Table 56: AstraZeneca Plc: Recent Developments, 2020-2023
Table 57: AstraZeneca Plc: Product Portfolio
Table 58: Bio-Rad Laboratories Inc.: Annual Revenue, 2022
Table 59: Bio-Rad Laboratories Inc.: Recent Developments, 2022 and 2023
Table 60: Bio-Rad Laboratories Inc.: Product Portfolio
Table 61: Cergentis B.V.: Recent Developments, 2020-2022
Table 62: Cergentis B.V.: Product Portfolio
Table 63: Exact Sciences Corp.: Annual Revenue, 2021
Table 64: Exact Sciences Corp.: Recent Developments, 2021-2023
Table 65: Exact Sciences Corp.: Product Portfolio
Table 66: Guardant Health Inc.: Annual Revenue, 2022
Table 67: Guardant Health Inc.: Recent Developments, 2021-2023
Table 68: Guardant Health Inc.: Product Portfolio
Table 69: Illumina Inc.: Annual Revenue, 2022
Table 70: Illumina, Inc.: Recent Developments, 2021-2023
Table 71: Illumina Inc.: Product Portfolio
Table 72: Invitae: Annual Revenue, 2022
Table 73: Invitae: Recent Developments, 2020-2023
Table 74: Invitae: Product Portfolio
Table 75: Invivoscribe Inc.: Recent Developments, 2021-2023
Table 76: Invivoscribe Inc.: Product Portfolio
Table 77: Natera Inc.: Annual Revenue, 2022
Table 78: Natera Inc.: Recent Developments, 2022 and 2023
Table 79: Natera Inc.: Product Portfolio
Table 80: NeoGenomics Inc.: Annual Revenue, 2022
Table 81: NeoGenomics Inc.: Recent Developments, 2021-2023
Table 82: NeoGenomics Inc.: Product Portfolio
Table 83: Qiagen N.V.: Annual Revenue, 2022
Table 84: Qiagen N.V.: Recent Developments, 2021-2023
Table 85: Qiagen N.V.: Product Portfolio
Table 86: Sysmex Corp.: Annual Revenue, 2023
Table 87: Sysmex Corp.: Recent Developments, 2021-2023
Table 88: Sysmex Corp.: Product Portfolio

List of Figures
Summary Figure: Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 1: Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 2: Rate of New Malignant Hematologic Cancers, by Age at Diagnosis, 2021
Figure 3: Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 4: Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, 2021-2028
Figure 5: Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, 2021-2028
Figure 6: Global Market for Next Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, 2021-2028
Figure 7: Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, 2021-2028
Figure 8: Global Market for Minimal Residual Disease Testing, by Application, 2021-2028
Figure 9: Distribution Share of Estimated New Cases of Hematological Malignancies, 2021
Figure 10: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, 2021-2028
Figure 11: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, 2021-2028
Figure 12: Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, 2021-2028
Figure 13: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, 2021-2028
Figure 14: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, 2021-2028
Figure 15: Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, 2021-2028
Figure 16: Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, 2021-2028
Figure 17: Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, 2021-2028
Figure 18: Global Market for Minimal Residual Disease Testing for Solid Tumors, by Region, 2021-2028
Figure 19: Global Market for Minimal Residual Disease Testing for Other Applications, by Region, 2021-2028
Figure 20: Global Market for Minimal Residual Disease Testing, by Region, 2021-2028
Figure 21: U.S. Elderly (65 and Above) Population, 2010-2050
Figure 22: 5-Year Relative Survival for Malignant Hematologic Cancers, by Cancer Type, 2022
Figure 23: North American Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 24: North American Market for Minimal Residual Disease Testing, by Application, 2021-2028
Figure 25: North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
Figure 26: European Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 27: European Market for Minimal Residual Disease Testing, by Application, 2021-2028
Figure 28: European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
Figure 29: Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 30: Asia-Pacific Market for Minimal Residual Disease Testing, by Application, 2021-2028
Figure 31: Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
Figure 32: Rest of the World Market for Minimal Residual Disease Testing, by Technology, 2021-2028
Figure 33: Rest of the World Market for Minimal Residual Disease Testing, by Application, 2021-2028
Figure 34: Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028
Figure 35: Snapshot: Key ESG Trends in Minimal Residual Disease Testing Industry
Figure 36: M&A in Minimal Residual Disease Testing Industry, by Year, 2020-2023
Figure 37: Leading Market Players Ranking, 2022
Figure 38: Global Minimal Residual Disease Testing Market Share, Competitive Intelligence, 2020-2023
Figure 39: Adaptive Biotechnologies Corp.: Annual Revenue, 2021 and 2022
Figure 40: Adaptive Biotechnologies Corp.: Revenue Share, by Business Unit, 2021
Figure 41: Amgen Inc.: Annual Revenue, 2021 and 2022
Figure 42: Amgen Inc.: Revenue Share, by Product, 2022
Figure 43: Amgen Inc.: Revenue Share, by Geography, 2022
Figure 44: AstraZeneca Plc.: Annual Revenue, 2021 and 2022
Figure 45: AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
Figure 46: AstraZeneca Plc: Revenue Share, by Region, 2022
Figure 47: Bio-Rad Laboratories Inc.: Annual Revenue, 2021 and 2022
Figure 48: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, 2022
Figure 49: Bio-Rad Laboratories Inc.: Revenue Share, by Region, 2022
Figure 50: Exact Sciences Corp.: Annual Revenue, 2020 and 2021
Figure 51: Exact Sciences Corp.: Revenue Share, by Business Unit, 2022
Figure 52: Guardant Health Inc.: Annual Revenue, 2021 and 2022
Figure 53: Guardant Health Inc.: Revenue Share, by Business Unit, 2022
Figure 54: Guardant Health Inc.: Revenue Share, by Region, 2022
Figure 55: Illumina Inc.: Annual Revenue, 2021 and 2022
Figure 56: Illumina Inc.: Revenue Share, by Business Unit, 2022
Figure 57: Illumina Inc.: Revenue Share, by Region, 2022
Figure 58: Invitae: Annual Revenue, 2021 and 2022
Figure 59: Invitae: Revenue Share, by Business Unit, 2022
Figure 60: Invitae: Revenue Share, by Product, 2022
Figure 61: Natera Inc.: Annual Revenue, 2021 and 2022
Figure 62: Natera Inc.: Revenue Share, by Business Unit, 2022
Figure 63: Natera Inc.: Revenue Share, by Region, 2022
Figure 64: NeoGenomics Inc.: Annual Revenue, 2021 and 2022
Figure 65: NeoGenomics Inc.: Revenue Share, by Business Unit, 2022
Figure 66: Qiagen N.V.: Annual Revenue, 2021 and 2022
Figure 67: Qiagen N.V.: Revenue Share, by Business Unit, 2022
Figure 68: Qiagen N.V.: Revenue Share, by Region, 2022
Figure 69: Sysmex Corp.: Annual Revenue, 2022 and 2023
Figure 70: Sysmex Corp.: Revenue Share, by Region, 2023

Executive Summary

With the development of new and efficient medications and the accessibility of immunotherapy, such as targeted antibodies and adoptive cell therapy, the landscape of cancer treatment has undergone a significant transformation over the past 10 years. Clinical trials are now being supported by minimal residual disease (MRD) testing as a helpful tool in dynamic risk-adapted treatment. Currently, minimal residual disease testing has been used in several clinical trials with a variety of purposes such as a predictive marker, as a tool to assess treatment effectiveness and compare various treatment modalities as well as an adaptive therapeutic method based on MRD status and its follow-up, particularly in maintenance period and early salvage approach.

Doctors can better anticipate potential outcomes when they weigh their treatment options when they have more specific knowledge about a patient’s illness condition or clinical understanding into how that patient has responded to therapy. An ever-expanding number of clinical evidence and real-world data supports the significance of MRD as a crucial marker of outcomes in patients with blood malignancies, which is even more crucial given that newer medications enable stronger responses and more persistent remissions.

Additionally, rising investments in MRD testing programs are anticipated to fuel market expansion. Growing research in the areas of MRD diagnostics and monitoring has been observed in the market, which is fueling demand. For instance, in January 2021, GRAIL worked with leading healthcare companies to assess the effectiveness of Grail’s methylation-based platform for MRD identification.

Companies Mentioned

  • Adaptive Biotechnologies Corp.
  • Amgen Inc.
  • Astrazeneca plc
  • Bio-Rad Laboratories Inc.
  • Cergentis B.V.
  • Exact Sciences Corp.
  • Guardant Health Inc.
  • Illumina Inc. (Grail LLC)
  • Invitae
  • Invivoscribe Inc.
  • Natera Inc.
  • Neogenomics Inc.
  • Qiagen
  • Sysmex Corp.

Table Information

Report AttributeDetails
No. of Pages152
PublishedJuly 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 2.2 Billion
Forecasted Market Value ( USD ) by 2028 $ 4.3 Billion
Compound Annual Growth Rate14.3%
Regions CoveredGlobal
No. of Companies Mentioned14

Related Topics

Related Reports

Minimal Residual Disease Testing Market by Technology, Application, End User, and Region 2024-2032 - Product Image

Minimal Residual Disease Testing Market by Technology, Application, End User, and Region 2024-2032

  • Report
  • 141 Pages
  • Global
From
Minimal Residual Disease Testing Global Market Report 2024 - Product Image

Minimal Residual Disease Testing Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Minimal Residual Disease Testing Market by Technology, Indication, End-User - Global Forecast 2025-2030 - Product Image

Minimal Residual Disease Testing Market by Technology, Indication, End-User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Minimal Residual Disease (MRD) Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
Minimal Residual Disease Testing Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032) - Product Image

Minimal Residual Disease Testing Market Innovations and Strategic Insights Report - Market Data, Trends, Market Potential, Competitive Analysis and Growth Forecasts (2024 to 2032)

  • Report
  • 154 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.